Gina Columbus

The FDA has approved dasatinib (Sprycel, Briston-Myers Squibb) tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.

The FDA granted an accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Officials with the FDA have granted accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.

he FDA has expanded the approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy (IST) to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Selinexor is indicated for patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or CAR T-cell therapy.